文献速递间质性肺疾病

低剂量吸入一氧化碳治疗特发性肺纤维化的II期临床试验

A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis.
PubMed 文献 · Chest · 2017-10-31

主要终点为血清MMP7浓度变化,结果显示两组间差异无统计学显著性;吸入一氧化碳耐受性良好,未观察到安全信号差异,但各项疗效终点均无显著改善。

要点

  • 吸入一氧化碳在门诊环境下对IPF患者耐受性良好、可安全给药。
  • 12周后血清MMP7变化两组间无显著差异(-0.90 ng/mL;95%CI -4.18~2.38)。
  • 生理指标、急性加重、住院、死亡及患者报告结局均无差异。

核心结论

  • 吸入一氧化碳对IPF患者安全且耐受良好,但未使研究终点发生显著变化。
  • 研究结果支持在未来IPF临床试验中检验吸入疗法的疗效。

研究设计与样本

  • 多中心、IIa期、双盲、假对照临床试验。
  • 给药方案为每日2小时、每周2次、持续12周。
  • 主要终点为治疗12周后血清MMP7浓度变化差值。

主要发现

  • 第12周MMP7组间差异为-0.90 ng/mL(95%CI,-4.18至2.38 ng/mL),无统计学显著性。
  • 肺功能、6分钟步行距离等生理指标未见组间差异。
  • 急性加重、住院、死亡发生率及患者报告结局无差异。
  • 两组不良事件分布无差异。

临床怎么用

  • 现有证据不支持将低剂量吸入一氧化碳用于IPF的常规治疗。
  • 门诊条件下吸入一氧化碳给药的安全性数据可为后续吸入疗法试验设计提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preclinical studies have demonstrated that low-dose carbon monoxide (CO) can abrogate experimental lung fibrosis. To test the therapeutic role of inhaled CO, we designed a clinical study in patients with idiopathic pulmonary fibrosis (IPF). METHODS: We conducted a multicenter, phase IIa, double-blinded, sham-controlled, clinical trial. Patients with IPF were randomized to treatment with inhaled CO at 100 to 200 parts per million or to inhaled 21% oxygen for 2 h daily, twice weekly, for 12 weeks. The primary study end point was the difference in change in matrix metalloproteinase-7 (MMP7) serum concentration after 12 weeks of treatment. Secondary end points included pulmonary function test measures, 6-min walk distance, rates of adverse events, acute exacerbation, hospitalization and death, and quality of life measures. RESULTS: Fifty-eight subjects were randomized to treatment with inhaled CO (n = 29) or placebo (n = 29). Despite modest increases in CO blood levels, the change in MMP7 concentrations after 12 weeks of treatment did not significantly differ between the study arms (MMP7 difference at week 12, -0.90 ng/mL; 95% CI, -4.18 to 2.38 ng/mL). No differences were observed in physiologic measures, incidence of acute exacerbations, hospitalization, death, or patient-reported outcomes. Importantly, no differences in distribution of adverse events were noted between the treatment arms. CONCLUSIONS: Inhaled CO is well tolerated and can be safely administered to patients with IPF in the ambulatory setting; however, inhaled CO did not result in significant changes in study end points. Our findings support testing the efficacy of inhaled therapies in future IPF clinical trials. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01214187; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Rosas IO, Goldberg HJ, Collard HR, et al. A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest. 2017. PMID: 29100885. doi:10.1016/j.chest.2017.09.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。